Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage

Expert Opinion on Therapeutic Patents · Published 2026-07-26 · DOI 10.1080/13543776.2026.2710227

Free full text

Authors (2)

Christian Gege, Gerald Kleymann

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Gege, C., Kleymann, G. (2026). Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage. Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2026.2710227

Related articles

• Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly Biosciences Inc · Expert Opinion on Therapeutic Patents · 2025 · Cites or is cited by this article · Same journal
• A novel inhibitor of human cytomegalovirus acts through a specific antiviral mechanism that involves the helicase-primase complex · Antimicrobial Agents and Chemotherapy · 2026 · Cites or is cited by this article
• Susceptibility of clinical isolates, laboratory-adapted and drug-resistant herpes simplex virus strains to helicase-primase inhibitor adibelivir (IM-250) and its synergy in combination therapy with acyclovir, penciclovir and foscarnet · ANTIVIRAL RESEARCH · 2026 · Cites or is cited by this article
• Sirtuin modulators: a review of patents from 2020 to 2024 · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 – present) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• Therapeutic applications of benzoxaborole compounds: a patent and literature analysis (2019–2024) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• An updated patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2020–2025) · Expert Opinion on Therapeutic Patents · 2026 · Same journal
• 5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present) · Expert Opinion on Therapeutic Patents · 2026 · Same journal
• PCSK9 inhibitors: an updated patent review 2024–2025 · Expert Opinion on Therapeutic Patents · 2026 · Same journal
• Topoisomerase II inhibitors in oncology: an updated patent review (2016-present) · Expert Opinion on Therapeutic Patents · 2025 · Same journal